• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

不同代 HIV-1 融合抑制剂之间的相互作用及其组合产生协同抗 HIV-1 作用的潜在机制。

Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

机构信息

Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

出版信息

FASEB J. 2012 Mar;26(3):1018-26. doi: 10.1096/fj.11-195289. Epub 2011 Nov 15.

DOI:10.1096/fj.11-195289
PMID:22085645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3289504/
Abstract

We previously reported that the combinatorial use of T20 and T1144, the first and next generations of HIV fusion inhibitors, containing different functional domains resulted in synergistic anti-HIV-1 effect, but this effect diminished when T20 and T1144 were covalently linked together. To elucidate the mechanism underlying this synergistic anti-HIV-1 effect, we studied the interactions between T20 and T1144 either in a mixture state or in a covalently linked state. T20 alone in solution was largely featureless, while T1144 alone was in α-helical trimeric conformation. When mixed in solution, T20 and T1144 showed a loose and transient interaction, with a moderate 10% α-helical content increase, but this interaction was greatly enhanced in the linked state, and T20 and T1144 showed ∼100% α-helical content. These results suggested that the loose and transient interaction between T20 and T1144 may destabilize the T1144 trimer, which makes its otherwise shielded binding sites more accessible to N-terminal heptad repeat (NHR) and increases its associating rate, thus increasing its anti-HIV-1 potency against the temporarily exposed target in NHR and causing the synergistic anti-HIV-1 effect. However, the strong interaction between T20 and T1144 in the covalently linked state may shield their NHR-binding sites, resulting in reduction of the synergistic effect.

摘要

我们之前曾报道,HIV 融合抑制剂第一代和第二代产品 T20 和 T1144 的联合使用具有协同抗 HIV-1 效果,这两种抑制剂含有不同的功能结构域,但当 T20 和 T1144 共价连接时,这种协同效果会减弱。为了阐明这种协同抗 HIV-1 效果的机制,我们研究了 T20 和 T1144 在混合物状态或共价连接状态下的相互作用。单独在溶液中的 T20 没有明显特征,而单独的 T1144 处于 α-螺旋三聚体构象。当混合在溶液中时,T20 和 T1144 表现出松散和短暂的相互作用,α-螺旋含量增加了 10%,但这种相互作用在连接状态下大大增强,T20 和 T1144 显示出约 100%的 α-螺旋含量。这些结果表明,T20 和 T1144 之间的松散和短暂相互作用可能使 T1144 三聚体不稳定,从而使原本被屏蔽的结合位点更容易被 N 端七肽重复序列(NHR)接近,并增加其结合率,从而增加其针对 NHR 中暂时暴露的靶标的抗 HIV-1 效力,从而产生协同抗 HIV-1 效果。然而,在共价连接状态下,T20 和 T1144 之间的强相互作用可能会屏蔽它们的 NHR 结合位点,从而降低协同效应。

相似文献

1
Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.不同代 HIV-1 融合抑制剂之间的相互作用及其组合产生协同抗 HIV-1 作用的潜在机制。
FASEB J. 2012 Mar;26(3):1018-26. doi: 10.1096/fj.11-195289. Epub 2011 Nov 15.
2
Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.第一代和下一代人类免疫缺陷病毒(HIV)融合抑制剂的组合对恩夫韦肽敏感和耐药的1型HIV毒株具有高效的协同作用。
J Virol. 2009 Aug;83(16):7862-72. doi: 10.1128/JVI.00168-09. Epub 2009 Jun 3.
3
HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.在gp41口袋区域具有单点突变的HIV-1变体,对具有口袋或膜结合结构域的HIV融合抑制剂表现出不同的敏感性。
Biochim Biophys Acta. 2012 Dec;1818(12):2950-7. doi: 10.1016/j.bbamem.2012.07.020. Epub 2012 Jul 31.
4
The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.HIV-1 gp41 富含色氨酸基序可与 N 端深袋位结合:对 gp41 结构与功能及其抑制剂的新认识。
J Virol. 2019 Dec 12;94(1). doi: 10.1128/JVI.01358-19.
5
The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120.作为HIV进入抑制剂靶点的C4区域——T20与gp120相互作用片段的核磁共振图谱分析
FEBS J. 2015 Dec;282(24):4643-57. doi: 10.1111/febs.13541. Epub 2015 Oct 22.
6
Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.创建人工尾部锚定物作为增强基于肽的HIV融合抑制剂效力的新策略。
J Virol. 2016 Dec 16;91(1). doi: 10.1128/JVI.01445-16. Print 2017 Jan 1.
7
Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.重新探讨恩夫韦肽的作用机制,并通过针对 gp41 中的三个靶点设计一个类似物来提高融合抑制活性。
AIDS. 2019 Aug 1;33(10):1545-1555. doi: 10.1097/QAD.0000000000002208.
8
Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.HIV-1抑制肽T20与gp41 N-HR卷曲螺旋的相互作用
J Biol Chem. 2009 Feb 6;284(6):3619-27. doi: 10.1074/jbc.M809269200. Epub 2008 Dec 10.
9
Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.对HIV-1对三代融合抑制剂敏感性的详细机制洞察。
J Biol Chem. 2009 Sep 25;284(39):26941-50. doi: 10.1074/jbc.M109.004416. Epub 2009 Jul 17.
10
A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.一种新型嵌合蛋白类 HIV-1 融合抑制剂,针对 gp41 糖蛋白具有高效力和稳定性。
J Biol Chem. 2011 Aug 12;286(32):28425-34. doi: 10.1074/jbc.M111.241992. Epub 2011 Jun 20.

引用本文的文献

1
A Bifunctional SARS-CoV-2 Entry Inhibitor Targeting the Host Protease TMPRSS2 and Viral Spike Protein HR1 Region.一种靶向宿主蛋白酶TMPRSS2和病毒刺突蛋白HR1区域的双功能SARS-CoV-2进入抑制剂。
Int J Mol Sci. 2025 Aug 26;26(17):8289. doi: 10.3390/ijms26178289.
2
Current ARTs, Virologic Failure, and Implications for AIDS Management: A Systematic Review.当前的抗逆转录病毒疗法、病毒学失败及其对艾滋病管理的影响:系统评价。
Viruses. 2023 Aug 13;15(8):1732. doi: 10.3390/v15081732.
3
Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.HIV-1 包膜糖蛋白 N 端七肽重复区中 Glu560 的突变有助于抵抗病毒进入的肽抑制剂。
Retrovirology. 2019 Dec 3;16(1):36. doi: 10.1186/s12977-019-0496-8.
4
De Novo Design of α-Helical Lipopeptides Targeting Viral Fusion Proteins: A Promising Strategy for Relatively Broad-Spectrum Antiviral Drug Discovery.从头设计靶向病毒融合蛋白的α-螺旋脂肽:一种有前途的相对广谱抗病毒药物发现策略。
J Med Chem. 2018 Oct 11;61(19):8734-8745. doi: 10.1021/acs.jmedchem.8b00890. Epub 2018 Sep 19.
5
Generation of a long-acting fusion inhibitor against HIV-1.一种针对HIV-1的长效融合抑制剂的生成。
Medchemcomm. 2018 Jun 6;9(7):1226-1231. doi: 10.1039/c8md00124c. eCollection 2018 Jul 1.
6
An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications.一种用于在包膜病毒表面糖蛋白中重现N端七肽重复三聚体以用于治疗应用的有效策略。
Chem Sci. 2016 Mar 1;7(3):2145-2150. doi: 10.1039/c5sc04046a. Epub 2015 Dec 3.
7
Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection.针对 HIV-1 感染的嵌合 gp41 N 端七肽重复螺旋三聚体的定点异肽桥连接。
Sci Rep. 2016 Aug 26;6:32161. doi: 10.1038/srep32161.
8
Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket.针对 gp41 口袋的 HIV-1 进入抑制剂的鉴定方法。
Viruses. 2013 Jan 11;5(1):127-49. doi: 10.3390/v5010127.

本文引用的文献

1
A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.一种新型嵌合蛋白类 HIV-1 融合抑制剂,针对 gp41 糖蛋白具有高效力和稳定性。
J Biol Chem. 2011 Aug 12;286(32):28425-34. doi: 10.1074/jbc.M111.241992. Epub 2011 Jun 20.
2
Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.开发针对 gp41 的肽和小分子 HIV-1 融合抑制剂。
ChemMedChem. 2010 Nov 8;5(11):1813-24. doi: 10.1002/cmdc.201000289.
3
Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.三环壬烷甲酰胺衍生物作为新型抗 HIV-1 药物。
Eur J Med Chem. 2010 Sep;45(9):4096-103. doi: 10.1016/j.ejmech.2010.05.070. Epub 2010 Jun 9.
4
Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.融合抑制剂结合后 HIV-1 gp41 的不对称失活。
PLoS Pathog. 2009 Nov;5(11):e1000674. doi: 10.1371/journal.ppat.1000674. Epub 2009 Nov 26.
5
Role of a putative gp41 dimerization domain in human immunodeficiency virus type 1 membrane fusion.推测的 gp41 二聚化结构域在人类免疫缺陷病毒 1 型膜融合中的作用。
J Virol. 2010 Jan;84(1):201-9. doi: 10.1128/JVI.01558-09.
6
Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.第一代和下一代人类免疫缺陷病毒(HIV)融合抑制剂的组合对恩夫韦肽敏感和耐药的1型HIV毒株具有高效的协同作用。
J Virol. 2009 Aug;83(16):7862-72. doi: 10.1128/JVI.00168-09. Epub 2009 Jun 3.
7
Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.稳定的人免疫缺陷病毒1型gp41延伸卷曲螺旋作为高亲和力融合抑制剂检测中的有效靶点。
Antimicrob Agents Chemother. 2009 Jun;53(6):2444-9. doi: 10.1128/AAC.00150-09. Epub 2009 Apr 13.
8
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.恩夫韦肽和西夫韦肽联合应用的协同疗效,这两种药物分别为第一代和第二代 HIV 融合抑制剂。
AIDS. 2009 Mar 13;23(5):639-41. doi: 10.1097/QAD.0b013e328325a4cd.
9
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.SC29EK是一种具有增强α-螺旋性的肽融合抑制剂,可抑制对恩夫韦肽耐药的1型人类免疫缺陷病毒突变体的复制。
Antimicrob Agents Chemother. 2009 Mar;53(3):1013-8. doi: 10.1128/AAC.01211-08. Epub 2008 Dec 29.
10
Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.静电约束α-螺旋肽抑制对恩夫韦肽耐药的HIV-1复制。
Int J Biochem Cell Biol. 2009 Apr;41(4):891-9. doi: 10.1016/j.biocel.2008.08.039. Epub 2008 Sep 10.